Fasciculoventricular Pathways Responsible for Ventricular Preexcitation in Patients with Danon Disease
Yang Liu,Feng Wang,Xin Chen,Yingcong Liang,Hai Deng,Hongtao Liao,Fang Rao,Wei,Qianhuan Zhang,Bin Zhang,Xianzhang Zhan,Xianhong Fang,Sandeep Nair,Michael Shehata,Xunzhang Wang,Yumei Xue,Shulin Wu
DOI: https://doi.org/10.1161/circep.118.006704
2018-01-01
Abstract:HomeCirculation: Arrhythmia and ElectrophysiologyVol. 11, No. 9Fasciculoventricular Pathways Responsible for Ventricular Preexcitation in Patients With Danon Disease Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissionsDownload Articles + Supplements ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toSupplementary MaterialsFree AccessLetterPDF/EPUBFasciculoventricular Pathways Responsible for Ventricular Preexcitation in Patients With Danon Disease Yang Liu, MD, PhD, Feng Wang, MD, Xin Chen, MD, Yingcong Liang, MD, Hai Deng, MD, Hongtao Liao, MD, Fang Rao, MD, PhD, Wei Wei, MD, Qianhuan Zhang, MD, Bin Zhang, MD, Xianzhang Zhan, MD, Xianhong Fang, MD, Sandeep Nair, MD, Michael Shehata, MD, Xunzhang Wang, MD, Yumei Xue, MD and Shulin Wu, MD Yang LiuYang Liu Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA (Y.L., S.N., M.S., X.W.). , Feng WangFeng Wang Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) , Xin ChenXin Chen Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) , Yingcong LiangYingcong Liang Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) , Hai DengHai Deng Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) , Hongtao LiaoHongtao Liao Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) , Fang RaoFang Rao Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) , Wei WeiWei Wei Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) , Qianhuan ZhangQianhuan Zhang Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) , Bin ZhangBin Zhang Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) , Xianzhang ZhanXianzhang Zhan Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) , Xianhong FangXianhong Fang Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) , Sandeep NairSandeep Nair Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA (Y.L., S.N., M.S., X.W.). , Michael ShehataMichael Shehata Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA (Y.L., S.N., M.S., X.W.). , Xunzhang WangXunzhang Wang Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA (Y.L., S.N., M.S., X.W.). , Yumei XueYumei Xue Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) and Shulin WuShulin Wu Shulin Wu, MD, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Rd, Guangzhou 510080, China. Email E-mail Address: [email protected] Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F.W., X.C., Y.L., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China (Y.L., F..W., X.C., H.D., H.L., F.R., W.W., Q.Z., B.Z., X.Z., X.F., Y.X., S.W.) Originally published13 Sep 2018https://doi.org/10.1161/CIRCEP.118.006704Circulation: Arrhythmia and Electrophysiology. 2018;11:e006704Danon disease, caused by the mutations in the gene of LAMP2(lysosome-associated membrane protein 2), is an X-linked dominant disorder classically characterized by the triad of cardiomyopathy, skeletal myopathy, and mental retardation.1,2 Cardiomyopathy typically manifests a hypertrophic phenotype; ventricular preexcitation is the most frequently encountered ECG abnormality in such patients and occurs in 68.2% of men and 26.7% of women.3 The pathological hallmark of Danon disease is intracytoplasmic vacuole accumulation containing glycogen granules and autophagic materials which lead to cardiac hypertrophy,1 but the underlying mechanism responsible for ventricular preexcitation continues to be a perplexing conundrum. The objective of this study was to determine the mechanism of ventricular preexcitation in patients with Danon disease.We enrolled 197 patients with unexplained left ventricular hypertrophy, and ventricular preexcitation was present in 10 (10 of 197; 5%) unrelated patients in whom genetic testing identified 3 (3 of 10; 30%) Danon disease patients with different LAMP2 mutations. Of the 3 patients, all were men aged 17 to 23 years at diagnosis, and electrophysiological study was performed in 2 patients.Intracardiac recordings in patient 1 demonstrated a slightly short His-ventricular (HV) interval of 30 ms, and local ventricular activation recorded at the His bundle area significantly earlier than the right ventricular apex during sinus rhythm (see the first beat in the Figure [A]). During ventricular overdrive stimulation, ventriculoatrial (VA) conduction was decremental and concentric with the earliest atrial retrograde activation at the His bundle, and the activation sequence of His bundle and right bundle (RB) was noted to be similar to sinus activation with H-RB sequence (Figure [A]). The deflections of the RB electrogram during sinus rhythm and ventricular pacing were −/+ and +/−, respectively; the deflection of the His bundle electrogram was −/+/− during both sinus rhythm and ventricular pacing, suggesting that the His activation during ventricular pacing was orthodromic, while the RB potential was activated retrograde. Atrial programmed stimulation resulted in prolongation of the atrio-His (AH) and atrioventricular (AV) intervals without changing QRS morphologies and HV intervals (Figure [B]), thereby excluding the presence of antegrade conduction over an accessory pathway connecting the atrium to the ventricle. These findings favor the diagnosis of a fasciculoventricular (FV) pathway with bidirectional conduction which takes off from the proximal part of the His bundle, bypasses conduction over the distal portion of the His bundle, the bundle branches, and Purkinje system and hence, is responsible for ventricular preexcitation and early local ventricular activation at the His bundle region during sinus rhythm, as well as the H-RB activation sequence during ventricular pacing (Figure [C] and [D]).Download figureDownload PowerPointFigure. Electrophysiological characteristics and schematic diagrams of fasciculoventricular pathways. A, Tracings obtained from electrophysiological study in patient 1. Midventricular pacing demonstrates decremental and concentric VA conduction with Wenckebach block phenomenon (a long-dotted line used as reference). Note that the earliest ventricular depolarization is seen on the His recording during sinus rhythm (a long-dotted line used as reference), and the His deflections precede the right bundle deflections during midventricular pacing (short-dotted lines used as reference). B, Atrial pacing demonstrates decremental AV conduction with a constant HV interval of 30 ms. C, Schematic illustrations of cardiac conduction in the absence or presence of fasciculoventricular connections. Left, During sinus rhythm, atrial activation in the normal heart proceeds over AV node, the His bundle, and bundle branches to ventricles so that the earliest ventricular activation occurs in the apical portion. Right, Atrial activation in the presence of a fasciculoventricular pathway proceeds through AV node to the His bundle and downward over the fasciculoventricular bypass tract as well as the distal portion of the His bundle and bundle branches to ventricles so that early ventricular activation in the basal portion of the right ventricle occurs with a short HV interval and a manifestation of ventricular preexcitation. D, Left, Midventricular pacing in the normal heart results in a right bundle (RB)-H activation sequence consistent with ventricular activation through the right bundle to the His bundle. Right, Midventricular pacing in the presence of retrograde fasciculoventricular pathway conduction causes a reversed H-RB activation sequence consistent with ventricular activation through the fasciculoventricular bypass tract to the His bundle. E, Tracings obtained from electrophysiological study in patient 2. Atrial pacing demonstrates decremental AV conduction with a constant HV interval of 22 ms. Note that earlier ventricular activation of the proximal than the distal site of the His bundle is seen (a long-dotted line used as reference). F, Prolongation of PR intervals with no change in the degree of ventricular preexcitation and HV intervals until progression to complete AV block during adenosine administration. A indicates atrial wave; AV, atrioventricular; AVN, atrioventricular node; FV, fasciculoventricular pathway; H, His bundle; HV, His-ventricular; LBB, left bundle branch; P, P wave; RBB, right bundle branch; SR, sinus rhythm; and VA, ventriculoatrial.In patient 2, the baseline HV intervals measured 22 ms during sinus rhythm. With programmed atrial stimulation, AV conduction was decremental with evidence of dual AV node physiology, but the HV intervals and degree of ventricular preexcitation remained constant (Figure [E]); local ventricular activation recorded from the proximal site of the His bundle was earlier than the distal His bundle and preceded the onset of surface delta waves by 15 ms (Figure [E]). These findings were also compatible with electrophysiological characteristics of an FV pathway.In both patients, adenosine challenge resulted in the prolongation of PR intervals with no change in the degree of ventricular preexcitation on surface ECG or HV intervals until progression to complete AV block (Figure [F]). No arrhythmias were inducible either with programmed extrastimulation or with burst pacing from both the coronary sinus and right ventricular apex. In the patient 3, despite no electrophysiological assessment performed, the presence of intermittent AV block indicated that the electrocardiographic preexcitation was because of an infranodal bypass tract consistent with an FV pathway (Figure in the Data Supplement).The underlying mechanism for the formation of FV connections is unknown but possible because of the disruption of the His bundle insulation, which was raised by the fact that the earliest ventricular activation was recorded at the His bundle region in our study. Anatomically, the His bundle is covered with a thin layer of myocardial fibers or courses directly within interventricular muscle in 79% of human hearts.4 When the fibrous sheath, which normally insulates the His bundle from superficial myocardial fibers, is disrupted by excessive accumulation of glycogen granules and autophagic materials, direct electrical connections from the His bundle to adjacent ventricular myocardium occur and lead to an acquired form of ventricular preexcitation. A similar mechanism was previously verified in a transgenic mouse overexpressing mutant PRKAG2, which resulted in glycogen storage cardiomyopathy and preexcitation findings.5 Cardiac histopathology revealed that the annulus fibrosis was disrupted by glycogen-filled myocytes.In summary, our study proved that ventricular preexcitation in patients with Danon disease was because of the presence of FV pathways characterized by bidirectional conduction and take-off from the proximal His bundle. The underlying mechanism for the formation of FV pathways warrants further study.AcknowledgmentsWe thank the patients who volunteered to participate in the study.Sources of FundingDr Liu receives research grants from the National Natural Science Foundation of China (NSFC-81400259) and Guangdong Province (2014A030310470). Dr Wu receives research grants from the Science and Technology Programs of Guangdong Province (no. 2014B070705005) and Guangzhou City (no. 201508020261).DisclosuresDr Liu receives an educational fee from Boston Scientific. The other authors report no conflicts.FootnotesThe Data Supplement is available with this article at https://www.ahajournals.org/doi/suppl/10.1161/CIRCEP.118.006704.https://www.ahajournals.org/journal/circep*Drs Liu, F. Wang, and Chen contributed equally to this work as first authors.Shulin Wu, MD, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Rd, Guangzhou 510080, China. Email [email protected]comReferences1. Yamada T, Shimojo S, Koori T, Mora M, Riggs JE, Oh SJ, Koga Y, Sue CM, Yamamoto A, Murakami N, Shanske S, Byrne E, Bonilla E, Nonaka I, DiMauro S, Hirano M. Primary lamp-2 deficiency causes x-linked vacuolar cardiomyopathy and myopathy (Danon disease).Nature. 2000; 406:906–910.CrossrefMedlineGoogle Scholar2. Danon MJ, Oh SJ, DiMauro S, Manaligod JR, Eastwood A, Naidu S, Schliselfeld LH. Lysosomal glycogen storage disease with normal acid maltase.Neurology. 1981; 31:51–57.CrossrefMedlineGoogle Scholar3. Boucek D, Jirikowic J, Taylor M. Natural history ofDanon disease.Genet Med. 2011; 13:563–568. doi: 10.1097/GIM.0b013e31820ad795CrossrefMedlineGoogle Scholar4. Kawashima T, Sasaki H. A macroscopic anatomical investigation of atrioventricular bundle locational variation relative to the membranous part of the ventricular septum in elderly human hearts.Surg Radiol Anat. 2005; 27:206–213. doi: 10.1007/s00276-004-0302-7CrossrefMedlineGoogle Scholar5. Arad M, Moskowitz IP, Patel VV, Ahmad F, Perez-Atayde AR, Sawyer DB, Walter M, Li GH, Burgon PG, Maguire CT, Stapleton D, Schmitt JP, Guo XX, Pizard A, Kupershmidt S, Roden DM, Berul CI, Seidman CE, Seidman JG. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy.Circulation. 2003; 107:2850–2856. doi: 10.1161/01.CIR.0000075270.13497.2BLinkGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Wang Y, Jia M, Guo Y, Zhang T and Ning B (2022) Case Report: Danon Disease: Six Family Members and Literature Review, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2022.842282, 9 Argirò A, Ho C, Day S, van der Velden J, Cerbai E, Saberi S, Tardiff J, Lakdawala N and Olivotto I (2022) Sex‐Related Differences in Genetic Cardiomyopathies, Journal of the American Heart Association, 11:9, Online publication date: 3-May-2022. Chen X, Fu L, He J, Bai R, Zeng S, Liao H, Deng H, Xue Y, Wu S and Liu Y (2022) A Frequent Observation of Wolff-Parkinson-White Syndrome and Fasciculoventricular Pathways in Patients With Danon Disease, Circulation Journal, 10.1253/circj.CJ-21-0572, 86:2, (309-318), Online publication date: 25-Jan-2022. Chen X, Li H, Liao H, Zhan X, Zhong Z, Zhang Q, Liu L, Liang Y, Deng H, Fang X, Xue Y, Wu S and Liu Y (2021) Clinical and genetic spectrum in Chinese families with Fabry disease: a single‐centre case series, ESC Heart Failure, 10.1002/ehf2.13638, 8:6, (5436-5444), Online publication date: 1-Dec-2021. Zhai Y, Miao J, Peng Y, Wang Y, Dong J and Zhao X (2021) Clinical features of Danon disease and insights gained from LAMP-2 deficiency models, Trends in Cardiovascular Medicine, 10.1016/j.tcm.2021.10.012, Online publication date: 1-Nov-2021. Darden D, Hsu J, Tzou W, von Alvensleben J, Brooks M, Hoffmayer K, Brambatti M, Sauer W, Feld G and Adler E (2021) Fasciculoventricular and atrioventricular accessory pathways in patients with Danon disease and preexcitation: A multicenter experience, Heart Rhythm, 10.1016/j.hrthm.2021.03.024, 18:7, (1194-1202), Online publication date: 1-Jul-2021. Gu W, Maimaitijiang A, Huang Q, Wu B, Sun S, Luo X, Li J and Xiong N (2021) Pseudo normalization of H–V interval due to intra-His block in a patient with fasciculoventricular accessory pathway, Journal of Electrocardiology, 10.1016/j.jelectrocard.2020.11.010, 64, (9-11), Online publication date: 1-Jan-2021. Lotan D, Salazar-Mendiguchía J, Mogensen J, Rathore F, Anastasakis A, Kaski J, Garcia-Pavia P, Olivotto I, Charron P, Biagini E, Baban A, Limongelli G, Ashram W, Wasserstrum Y, Galvin J, Zorio E, Iacovoni A, Monserrat L, Spirito P, Iascone M, Arad M, Mandel C, Morillas H, Gonzalez-Lopez E, Dominguez F, Marchetti D, Pezzoli L, Anne Walsh K, McGorrian C, Ditaranto R, Vitale G, Villard E, Richard P, Monda E, Caiazza M, Passantino S, Girolami F, Drago F, Adorisio R, Field E, Freimark D and Baandrup U (2020) Clinical Profile of Cardiac Involvement in Danon Disease, Circulation: Genomic and Precision Medicine, 13:6, Online publication date: 1-Dec-2020. Montañés M, Granados M, Valverde M, Palomino J, Fontenla A and Escribano L (2020) Wolff Parkinson white pattern in Danon disease: When preexcitation is not what it seems, Journal of Electrocardiology, 10.1016/j.jelectrocard.2020.08.020, 62, (161-164), Online publication date: 1-Sep-2020. Cenacchi G, Papa V, Pegoraro V, Marozzo R, Fanin M and Angelini C (2019) Review: Danon disease: Review of natural history and recent advances, Neuropathology and Applied Neurobiology, 10.1111/nan.12587, 46:4, (303-322), Online publication date: 1-Jun-2020. Hoffmayer K, Han F, Singh D and Scheinman M (2020) Variants of accessory pathways, Pacing and Clinical Electrophysiology, 10.1111/pace.13830, 43:1, (21-29), Online publication date: 1-Jan-2020. Zhang Y, Ren H and Zhou S (2020) A case report of delayed diagnosis of danon disease, Medicine, 10.1097/MD.0000000000022640, 99:40, (e22640) Soares Correa F, Lokhandwala Y, Sánchez‐Quintana D, Mori S, Anderson R, Wellens H and Back Sternick E (2019) Unusual variants of pre‐excitation: From anatomy to ablation: Part III—Clinical presentation, electrophysiologic characteristics, when and how to ablate nodoventricular, nodofascicular, fasciculoventricular pathways, along with considerations of permanent junctional reciprocating tachycardia, Journal of Cardiovascular Electrophysiology, 10.1111/jce.14247, 30:12, (3097-3115), Online publication date: 1-Dec-2019. Jhaveri S, Herber J, Zahka K, Boyle G, Saarel E and Aziz P (2019) Arrhythmias and fasciculoventricular pathways in patients with Danon disease: A single center experience, Journal of Cardiovascular Electrophysiology, 10.1111/jce.14049, 30:10, (1932-1938), Online publication date: 1-Oct-2019. Guo S, Zhou L, Wang R, Lv Z, Xu H, Han B, Korantzopoulos P, Hu F and Liu T (2019) Danon disease: Two patients with atrial fibrillation in a single family and review of the literature, Experimental and Therapeutic Medicine, 10.3892/etm.2019.7777 Liu Y, Chen X, Wang F, Liang Y, Deng H, Liao H, Zhang Q, Zhang B, Zhan X, Fang X, Shehata M, Wang X, Xue Y and Wu S (2019) Prevalence and clinical characteristics of Danon disease among patients with left ventricular hypertrophy and concomitant electrocardiographic preexcitation, Molecular Genetics & Genomic Medicine, 10.1002/mgg3.638, 7:5, (e638), Online publication date: 1-May-2019. September 2018Vol 11, Issue 9 Advertisement Article InformationMetrics © 2018 American Heart Association, Inc.https://doi.org/10.1161/CIRCEP.118.006704PMID: 30354295 Originally publishedSeptember 13, 2018 Keywordslysosomal-associated membrane protein 2heart ventriclesbundle of Hishypertrophy, left ventriculargenetic testingPDF download Advertisement SubjectsCardiomyopathyElectrophysiologyGeneticsPrecision Medicine
What problem does this paper attempt to address?
-
Single-nucleotide polymorphisms in SCN5A gene in Chinese Han population and their correlation with cardiac arrhythmias
JunZhu Chen,XuDong Xie,JianHua Zhu,QianMing Tao,XingXiang Wang
DOI: https://doi.org/10.1097/00125817-200405000-00009
IF: 8.864
2004-01-01
Genetics in Medicine
Abstract:To the Editor: The cardiac sodium channel gene (SCN5A) plays a key role in cardiac electrophysiology. Mutations in the gene have been implicated in a broad spectrum of familial cardiac arrhythmias, including long QT syndrome (LQTS), idiopathic ventricular fibrillation, cardiac conduction disease, and congenital sick sinus syndrome. In 2002, Splawski et al.,1 taking a new step in the genetic studies of arrhythmia, reported that a common polymorphism Y1102 in SCN5A might increase the risk of heart arrhythmia in members of the population at large. In addition, previous studies have suggested that some mild LQTS mutations might cause drug-induced LQTS, leading to the expectation that polymorphisms of LQTS-related genes (including SCN5A) will potentially provide useful information on acquired cardiac arrhythmia.2,3 The polymorphisms of SCN5A gene have been well studied in American and Japanese but not in Chinese. In this letter, we systematically analyzed a large data set of samples to determine the polymorphisms of SCN5A gene in Chinese Han nationality, and hence their contribution to cardiac arrhythmias. DNA samples of 240 independent healthy volunteers from Han nationality in China were directly sequenced. A total of five SNPs were identified, including three novel SNPs: one synonymous SNP in exon2 (G87A, Ala29Ala), one regulatory SNP in 3′ untranslated region (G6174A), and one in intron 23 adjacent to donor splicing site (4245 + 82A>G). A1673G (His558Arg) and C5457T (Asp1819Asp) had been reported in American and Japanese.4–6 S1102Y and the other 10 reported SNPs could not be detected in Chinese Hans. The frequencies of the five SNPs were as follows: G87A 27.8%, A1673G 10.6%, 4245 + 82A>G 32.7%, C5457T 41.6%, and G6174A 44.9%. Genotype distributions of all loci were in Hardy-Weinberg equilibrium in healthy volunteers (all P > 0.05). Comparing the distribution of A1673G and C5457T in Chinese Han population with those in other ethnic populations, we observed that there was no significantly statistical difference in the frequency of A1673G among different ethical populations (all P > 0.05). The frequency of C5457T in Chinese Han population was similar to that observed in Japanese (P > 0.5), but significantly higher than that in American (P < 0.005). To determine the correlation of identified SNPs with cardiac arrhythmias, 78 unrelated patients who suffered from cardiac arrhythmias including syncope, aborted sudden death, documented ventricular tachyarrhythmia, and acquired long QT syndrome were recruited. Of these identified SNPs, only the distribution of A1673G in arrhythmia patients significantly differed from that in healthy volunteers, and the allele G1673 was overrepresented inpatients with a value of P = 0.0000033. The likelihood of displaying signs of arrhythmia in a G1673 carrier (G, A and G, G) yielded an odds ratio of 3.01 [95% confidence interval 1.59 to 5.69, P < 0.005]. The odds ratio was not significantly altered after controlling for age and gender (P < 0.005). A1673G is a nonsynonymous SNP in the Na+channel interdomain cytoplasmic linker, resulting in an amino acid change from histidine to arginine. Recently, a series studies about a common SCN5A polymorphism A1673G (H558R) suggested that it could modulate the biophysical effects of a nearby mutation within the same gene.7,8 However, the incidence of it has not been systematically evaluated in a large set of patients with cardiac arrhythmia. Our results suggest it might be involved in susceptibility to cardiac arrhythmias in Chinese Han population. Additional studies will be required not only to detect its more exact prevalence rate with a larger sample size in cardiac arrhythmia but also to investigate the possible biophysical effects of A1673G on the channel function in coordination with other polymorphisms.
-
Identification of LAMP2 Mutations in Early-Onset Danon Disease with Hypertrophic Cardiomyopathy by Targeted Next-Generation Sequencing.
Lijun Fu,Sushan Luo,Shuang Cai,Wenjing Hong,Ying Guo,Jinjin Wu,Tingliang Liu,Chongbo Zhao,Fen Li,Huimin Huang,Meirong Huang,Jian Wang
DOI: https://doi.org/10.1016/j.amjcard.2016.06.037
IF: 3.133
2016-01-01
The American Journal of Cardiology
Abstract:Danon disease is an X-linked disorder with the clinical triad of cardiomyopathy, skeletal myopathy, and mental retardation. Early diagnosis of this disease remains a challenge, especially in the pediatric population. In this study, we developed a targeted panel-based next generation sequencing pipeline to identify mutations by sequencing of selected candidate genes in 136 pediatric patients with either hypertrophic cardiomyopathy (HC) or idiopathic dilated cardiomyopathy (IDC). This led to the identification of lysosomeassociated membrane protein 2 (LAMP2) mutations in 4 of the 64 (6%) probands with HC, including 3 novel nonsense mutations (p.Q240X, p.S250X, and p.G22X). No LAMP2 mutation was detected in the other 72 probands with IDC. All 4 probands and one additional affected family member (2 men and 3 women) had an early-onset age and presented either HC alone or combined with Wolff-Parkinson-White syndrome and skeletal myopathy. Immunofluorescence staining and Western blot analysis revealed absent LAMP2 expression in both cardiac and skeletal muscle samples of the first proband and severely decreased LAMP2 expression in the skeletal muscle samples of the second proband. In conclusion; cardiomyopathy in the patients with Danon disease may occur during early childhood and tend to be HC rather than IDC in both affected men and women. Therefore, Danon disease should be considered as one of the leading causes of unexplained ventricular hypertrophy in pediatric patients. The inclusion of LAMP2 gene in cardiomyopathy genetic screening panels may contribute to early diagnosis of Danon disease. (C) 2016 Elsevier Inc. All rights reserved.
-
Association Between SCN5A R225Q Variant and Dilated Cardiomyopathy: Potential Role of Intracellular Ph and WNT/β-catenin Pathway
Jingjing Hu,Kun Yang,Yongchao Zhao,Zilun Wei,Lebing Yang,Rifeng Gao,Yonghui Wu,Lei Xu,Sujuan Xu,Kai Hu,Aijun Sun,Junbo Ge
DOI: https://doi.org/10.1136/jmedgenet-2021-108396
2022-01-01
Journal of Medical Genetics
Abstract:BackgroundThe SCN5A variant is a common cause of familial dilated cardiomyopathy (DCM). We previously reported a SCN5A variant (c.674G>A), located in the high-risk S4 segment of domain I (DI-S4) region in patients with idiopathic DCM and R225Q knockin (p.R225Q) mice carrying the c.674G>A variant exhibited prolonged baseline PR intervals without DCM phenotypes. In this study, we explored the association and mechanism between R225Q variant and DCM phenotype.MethodsPrevalence of DI-S4 variant was compared between patients with idiopathic DCM and the control participants. R225Q knockin and wild-type (WT) mice were subjected to doxorubicin (DOX), D-galactose (D-gal) or D-gal combined with DOX.ResultsClinical data suggested that the prevalence of DI-S4 variant was higher in DCM group than in the control group (4/90 (4.4%) vs 3/1339 (0.2%), p<0.001). Cardiomyocytes from R225Q knockin mice treated with D-gal and DOX exhibited more significant hypertrophic phenotype and weaker contraction/dilation function and an increased level of apoptosis as compared with WT mice. Mechanistically, we found that R225Q variant could increase intracellular pH and further induce the activation of the WNT/β-catenin pathway as well as the overexpression of pro-hypertrophic and pro-apoptotic targets. WNT-C59 inhibitor improved cardiac function in the R225Q knockin mice treated with D-gal and DOX.ConclusionOur results suggest that R225Q variant is associated with increased susceptibility to DCM. Ageing could enhance this process via activating WNT/β-catenin signaling in response to increased intracellular pH. Antagonising the WNT/β-catenin pathway might be a potential therapeutic strategy for mitigating R225Q variant-related DCM pathogenesis.
-
Identification and functional analysis of a novel de novo missense mutation located in the initiation codon of LAMP2 associated with early onset female Danon disease
Yongxiang Wang,Ming Bai,Piyi Zhang,Yu Peng,Zixian Chen,Zhiyu He,Jin Xu,Youqi Zhu,Dongdong Yan,Runqing Wang,Zheng Zhang
DOI: https://doi.org/10.1002/mgg3.2216
Abstract:Background: Danon disease is characterized by the failure of lysosomal biogenesis, maturation, and function due to a deficiency of lysosomal membrane structural protein (LAMP2). Methods: The current report describes a female patient with a sudden syncope and hypertrophic cardiomyopathy phenotype. We identified the pathogenic mutations in patients by whole-exon sequencing, followed by a series of molecular biology and genetic approaches to identify and functional analysis of the mutations. Results: Suggestive findings by cardiac magnetic resonance (CMR), electrocardiogram (ECG), and laboratory examination suggested Danon disease which was confirmed by genetic testing. The patient carried a novel de novo mutation, LAMP2 c.2T>C located at the initiation codon. The quantitative polymerase chain reaction (qPCR) and Western blot (WB) analysis of peripheral blood leukocytes from the patients revealed evidence of LAMP2 haploinsufficiency. Labeling of the new initiation codon predicted by the software with green fluorescent protein followed by fluorescence microscopy and Western blotting showed that the first ATG downstream from the original initiation codon became the new translational initiation codon. The three-dimensional structure of the mutated protein predicted by alphafold2 revealed that it consisted of only six amino acids and failed to form a functional polypeptide or protein. Overexpression of the mutated LAMP2 c.2T>C showed a loss of function of the protein, as assessed by the dual-fluorescence autophagy indicator system. The mutation was confirmed to be null, AR experiments and sequencing results confirmed that 28% of the mutant X chromosome remained active. Conclusion: We propose possible mechanisms of mutations associated with haploinsufficiency of LAMP2: (1) The inactivation X chromosome carrying the mutation was not significantly skewed. However, it decreased in the mRNA level and the expression ratio of the mutant transcripts; (2) The identified mutation is null, and the active mutant transcript fails to translate into the normal LAMP2 proteins. The presence of haploinsufficiency in LAMP2 and the X chromosome inactivation pattern were crucial factors contributing to the early onset of Danon disease in this female patient.
-
Identification of a LMNA (c.646c > T) Variant by Whole-Exome Sequencing in Combination with a Dilated Cardiomyopathy (DCM) Related Gene Filter in a Family with Familiar DCM
Liang Chen,Zhou Zhongyin,Hang Lu,Yan Xie,Gang Li,Jianfei Huang,Zhao Dong-sheng
DOI: https://doi.org/10.7555/jbr.32.20180003
2018-01-01
Abstract:Dilated cardiomyopathy (DCM) is characterized by the dilated heart chambers and reduced systolic function in the absence of specific aetiology [1] .Approximately one third of DCM cases are hereditary.In recent years, DCM concomitant with arrhythmias and sudden death resulting from gene mutation has been widely reported [2] .In the current study, we report the identification of a mutation within lamin A (LMNA) (p.R216C) in a Han Chinese family with similar cardiac manifestations by using whole-exome sequencing in combination with a related gene filter and co-segregation analysis.The study was approved by the local Ethics Committee of the First People ' s Hospital of Nantong Jiangsu.A family from Jiangsu Province in eastern China was investigated with 24 hours-Holter monitoring and transthoracic echocardiography and the pedigree was built using Microsoft Office [3] .The information of the family members is shown in Fig. 1 and Table 1.Ⅲ4 (the proband, male, 53 years old) was hospitalized due to recurrent dizziness and amaurosis in 2012.The electrocardiogram showed grade 3 atrioventricular block (AVB), and a pacemaker was implanted.Both Ⅱ5 (male, 71 years old) and Ⅱ11 (male, 63 years old) had heart enlargement and pacemaker implantation for grade 3 AVB, and suffered from atrial fibrillation (2
-
Danon Disease Caused by Two Novel Mutations of the LAMP2 Gene: Implications for Two Ends of the Clinical Spectrum
Daojun Hong,Zhihong Shi,Zhaoxia Wang,Yun Yuan
DOI: https://doi.org/10.5414/np300465
IF: 1.136
2012-01-01
Clinical Neuropathology
Abstract:Danon disease is caused by mutations of the lysosome-associated membrane protein-2 (LAMP2) gene at Xq24. Male patients usually manifested as severe cardiomyopathy, mild myopathy and mental retardation. We describe two patients: the first patient presented with severe hypertrophic cardiomyopathy, Wolff-Parkinson-White syndrome, proximal muscle weakness, and chronic painless diarrhea; the second patient manifested as limb-girdle muscle weakness, mild left ventricular diastolic dysfunction, sub-clinical neuropathy. Muscle biopsies indicated autophagic vacuolar myopathy. Immunologic analysis demonstrated absence of the LAMP2 protein in the first patient, while a smear of expression was detected in the second patient. Two nonsense mutations (p.E298X and p. K402X) were identified in the two cases, respectively located in exon 7 and exon 9B of the LAMP2 gene. Our findings indicated that patients with Danon disease caused by mutations in exon 1 – 8 manifested as a typically severe phenotype, while patients with mutations in exon 9 of the LAMP2B isoform presented with a relatively benign phenotype.
-
Danon disease: a case report and literature review
Jiamin Xu,Zhu Li,Yihai Liu,Xinlin Zhang,Fengnan Niu,Hongyan Zheng,Lian Wang,Lina Kang,Kun Wang,Biao Xu
DOI: https://doi.org/10.1186/s13000-021-01100-8
2021-01-01
Diagnostic Pathology
Abstract:Background Danon disease (DD) is a rare x-linked dominant multisystemic disorder with a clinical triad of severe cardiomyopathy, skeletal myopathy, and mental retardation. It is caused by a defect in the lysosomal-associated membrane protein-2 ( LAMP 2) gene, which leads to the formation of autophagic vacuoles containing glycogen granule deposits in skeletal and cardiac muscle fibers. So far, more than 50 different mutations in LAMP 2 have been identified. Case presentation Here, we report an 18-year-old male patient who was hospitalized for heart failure. Biopsy of the left lateral femoral muscle revealed scattered autophagic vacuoles in the muscle fibers with increased glycogen. Next generation sequencing (NGS) was used to detect gene mutations of the proband sample and a novel frameshift mutation (c.1052delG) has been identified in exon 8 of LAMP 2, which leads to truncation of the protein. Conclusion We found a novel frameshift mutation, a hemizygous mutation (c.1052delG) in exon 8 of LAMP 2, identified as presenting the hypertrophic cardiomyopathy (HCM) phenotype. Genetic analysis is the gold standard for the diagnosis of DD and is essential to determine appropriate treatment strategies and to confirm the genetic risk of family members.
-
Next-generation Sequencing Identified Novel Desmoplakin Frame-Shift Variant in Patients with Arrhythmogenic Cardiomyopathy
Xiaoping Lin,Yuankun Ma,Zhejun Cai,Qiyuan Wang,Lihua Wang,Zhaoxia Huo,Dan Hu,Jian'an Wang,Meixiang Xiang
DOI: https://doi.org/10.1186/s12872-020-01369-5
2019-01-01
Abstract:BackgroundArrhythmogenic cardiomyopathy (AC) is one of the leading causes for sudden cardiac death (SCD). Recent studies have identified mutations in cardiac desmosomes as key players in the pathogenesis of AC. However, the specific etiology in individual families remains largely unknown.MethodsA 4-generation family presenting with syncope, lethal ventricular arrhythmia and SCD was recruited. Targeted next generation sequencing (NGS) was performed and validated by Sanger sequencing. Plasmids containing the mutation and wild type (WT) were constructed. Real-time PCR, western-blot and immunofluorescence were performed to detect the functional change due to the mutation.ResultsThe proband, a 56-year-old female, presented with recurrent palpitations and syncope. An ICD was implanted due to her family history of SCD/ aborted SCD. NGS revealed a novel heterozygous frame-shift variant (c.832delG) in Desmoplakin (DSP) among 5 family members. The variant led to frame-shift and premature termination, producing a truncated protein. Cardiac magnetic resonance (CMR) of the family members carrying the same variant shown myocardium thinning and fatty infiltration in the right ventricular, positive bi-ventricular late gadolinium enhancement and severe RV dysfunction, fulfilling the diagnostic criteria of AC. HEK293T cells transfected with mutant plasmids expressed truncated DSP mRNA and protein, upregulation of nuclear junction plakoglobin (JUP) and downregulation of beta-catenin, when compared with WT.ConclusionWe infer that the novel c.832delG variant in DSP was associated with AC in this family, likely through Wnt/beta-catenin signaling pathway.
-
Novel LAMP2 mutations in Chinese patients with Danon disease cause varying degrees of clinical severity.
Su-shan Luo,Jian-ying Xi,Shuang Cai,Chong-bo Zhao,Jia-hong Lu,Wen-hua Zhu,Jie Lin,Kai Qiao,Yin Wang,Zhu-rong Ye
DOI: https://doi.org/10.5414/NP300668
IF: 1.136
2014-01-01
Clinical Neuropathology
Abstract:Aims: Danon disease is an X-linked dominant lysosomal glycogen storage disorder characterized by cardiomyopathy, skeletal myopathy, and mental retardation. This study described two Chinese cases of Danon disease in order to broaden the phenotypic and genetic spectrum. Methods: Clinical data were collected and LAMP2 mutations were analyzed. Results: Patient A had fluctuating limb weakness during 6 months follow-up and was diagnosed with drug-induced myopathy due to anti-hepatitis B therapy with lamivudine. However, the first muscle biopsy with large cytoplasmic vacuoles confused the diagnosis and led to the second biopsy that allowed for the final diagnosis. Patient B had severe cardiac disturbances leading to sudden death. Molecularly, patient A harbored a synonymous mutation adjacent to the exon 6-intron 6 junction; mRNA analysis provided evidence that totally abolished the donor site and caused skipping of exon 6. Patient B harbored a frame-shift deletion mutation in exon 3 (c.396de1A) leading to a truncated protein. Discussion: To our knowledge, this is the first report of Danon disease caused by a synonymous exon mutation that affected mRNA splicing, which indicates that a synonymous substitution may not be silent when it is in the exon sequences close to the splice sites. It is also the first description of Danon disease clinically presenting as drug-induced myopathy at onset; the pathological changes might be the key point for making a differential diagnosis.
-
Clinical and genetic profile of Chinese children with Danon disease: A single-center retrospective cohort study
Qingni Zhang,Wenxiu Chan,Yiwei Chen,Jinjin Wu,Hao Chen,Tingting Yu,Ruen Yao,Lijun Chen,Bing Zhang,Hao Zhang,Zhen Zhang,Lijun Fu
DOI: https://doi.org/10.1016/j.cjca.2024.10.005
IF: 6.614
2024-10-13
Canadian Journal of Cardiology
Abstract:Background Danon disease (DD) is a rare X-linked dominant lysosomal storage disorder. Studies on DD pediatric patients are limited due to the small number of cases and challenges in early detection. Methods We retrospectively analyzed clinical and genetic data of 29 pediatric patients who visited our hospital for treatment or genetic counseling of DD from July 2014 to December 2023. Results The mean age at diagnosis was 7.2±5.9 years for males (n=21) and 9.4±5.0 years for females (n=8). Asymptomatic elevated liver aminotransferase and/or creatine kinase (CK) levels were initial manifestations detected in 10 (48%) male patients and absent in female patients. Hypertrophic cardiomyopathy (HCM) was observed in 20 (95%) male and 7 (88%) female patients, while dilated cardiomyopathy (DCM) was not detected. Ventricular preexcitation (VP) was observed initially in 10 (36%) patients and in 15 (54%) at latest evaluation. Patients with VP had higher left ventricular posterior wall thickness in diastole z-scores than those without VP (5.6±2.2 vs. 3.5±2.1, p=0.029). During a median 2.7-years follow-up, two males received heart transplants. One boy and one girl died of heart failure and sudden cardiac arrest, respectively. Twenty-three pathogenic LAMP2 variants were identified, including seven novel variants. Conclusions A retrospective review of 29 DD cases suggests an underrecognized asymptomatic period in male DD patients, characterized by elevations in serum CK and transaminases. HCM appears to be the only cardiac manifestation in pediatric female patients, unlike a high incidence of DCM in adult female patients. The incidence of VP may increase with disease progression.
cardiac & cardiovascular systems
-
A Family with Danon Disease Caused by a Splice Site Mutation in LAMP2 That Generates a Truncated Protein.
Nianwei Zhou,Jie Cui,Weipeng Zhao,Yingying Jiang,Wenqing Zhu,Lu Tang,Xuejie Li,Minmin Sun,Cuizhen Pan,Xianhong Shu
DOI: https://doi.org/10.1002/mgg3.561
2019-01-01
Molecular Genetics & Genomic Medicine
Abstract:Background Danon disease is an X-linked dominant hereditary condition caused by mutations in the gene encoding lysosomal-associated membrane protein 2 (LAMP2), leading to failure of lysosome binding to autophagosomes, accumulation of glycogen in the heart, and abnormal cardiac function. Methods We describe identification of a mutation in LAMP2, c.741+1G>T, in a family with Danon disease by whole exome sequencing. Results Pathology examination of patient skeletal muscle biopsy showed myogenic damage and autophagic vacuoles with sarcolemmal features (AVSF). Numerous autophagic vacuoles accumulated in muscle cells were detected by electron microscopy, indicating abnormal autophagy function. Conclusion The mutation did not result in loss of mRNA exons; rather, a 6-nucleotide (two-codon) insertion, where the latter was a stop codon, leading to early termination of LAMP2 protein translation. The resulting truncated protein lacks an important transmembrane domain, which will impair lysosome/autophagosome fusion, damage autophagy function, and result in the clinical manifestations of Danon disease.
-
Cardiovascular magnetic resonance findings in Danon disease: a case series of a family
Xiaolong Liu,Ning Zhai,Xiaoqiang Wang,Jiehuan Wang,Mengchun Jiang,Zhanguo Sun,Yueqin Chen,Jingjing Xu,Yinghua Cui,Lu Li
DOI: https://doi.org/10.3389/fcvm.2023.1159576
IF: 3.6
2023-05-04
Frontiers in Cardiovascular Medicine
Abstract:Background: Cardiac involvement constitutes the primary cause of mortality in patients with Danon disease (DD). This study aimed to explore the cardiac magnetic resonance (CMR) features and progressions of DD cardiomyopathies in a family with long-term follow-up. Methods: Seven patients (five females and two males), belonging to the same family and afflicted with DD, were enrolled in this study between 2017 and 2022. The cardiac structure, function, strain, tissue characteristics on CMR and their evolutions during follow-up were analyzed. Results: Three young female patients (3/7, 42.86%) exhibited normal cardiac morphology. Four patients (4/7, 57.14%) displayed left ventricle hypertrophy (LVH), and mostly with septal thickening (3/4, 75%). A single male case (1/7, 14.3%) showed decreased LV ejection fraction (LVEF). Nonetheless, the global LV strain of the four adult patients decreased in different degree. The global strain of adolescent male patients was decreased compared to the age-appropriate female patients. Five patients (5/7, 71.43%) exhibited late gadolinium enhancement (LGE), with proportion ranging from 31.6% to 59.7% (median value 42.7%). The most common LGE location was the LV free wall (5/5, 100%), followed by right ventricle insertion points (4/5, 80%) and intraventricular septum (2/5, 40%). Segmental radial strain ( r s = −0.586), circumferential strain ( r = 0.589), and longitudinal strain ( r = 0.514) were all moderately correlated with the LGE proportions of corresponding segments ( P < 0.001). T2 hyperintense and perfusion defect foci were identified, overlapping with the LGE areas. During follow-up, both the young male patients exhibited notable deterioration of their cardiac symptoms and CMR. The LVEF and strain decreased, and the extent of LGE increased year by year. One patient underwent T1 mapping examination. The native T1 value was sensitively elevated even in regions without LGE. Conclusions: Left ventricular hypertrophy, LGE with sparing or relatively less involved IVS, and LV dysfunction are prominent CMR features of Danon cardiomyopathy. Strain and T1 mapping may have advantages in detecting early-stage dysfunction and myocardial abnormalities in DD patients, respectively. Multi-parametric CMR can serve as an optimal instrument for detecting DD cardiomyopathies.
cardiac & cardiovascular systems
-
De novo LAMP2 insertion mutation causes cardiac-only Danon disease: A case report
James Jiqi Wang,Bo Yu,Xiuli Song,Hong Wang
DOI: https://doi.org/10.3389/fcvm.2022.899283
2022-09-16
Abstract:Danon disease is a rare disease caused by glycogen storage lysosomal disorder. It is related to the pathogenic mutation of the LAMP2 gene. In this case report, we present a patient with a novel pathogenic mutation (c.764_765insGA) with cardiac-only symptoms. Her family members do not carry the same mutation she does, suggesting this is a de novo mutation. Further tests revealed vacuoles and glycogen disposition in the patient's heart tissue and a significant decrease in LAMP2 protein expression. Protein structure remodeling of LAMP2 predicted that the mutant protein has conformational change lacking an important transmembrane domain, subsequently causing protein destabilization.
-
Detection of somatic and germline mosaicism for the LAMP2 gene mutation c.808dupG in a Chinese family with Danon disease.
Xiao-Ling Chen,Yan Zhao,Hai-Ping Ke,Wen-Ting Liu,Zhen-Fang Du,Xian-Ning Zhang
DOI: https://doi.org/10.1016/j.gene.2012.06.064
IF: 3.913
2012-01-01
Gene
Abstract:Danon disease is a rare X-linked lysosomal storage disease characterized by hypertrophic cardiomyopathy, myopathy and mental retardation, and is due to a primary defect in lysosome-associated membrane protein-2 (LAMP 2). More than 26 mutations in the LAMP2 gene have been described, including a small number of de novo mutations, some of which are suspected to be caused by germline mosaicism. Here, we describe the first molecularly documented evidence of somatic mosaicism for a LAMP2 mutation, identified in the asymptomatic mother of a boy with Danon disease caused by the frameshift mutation c.808dupG (p.A270Gfx3) within exon 6. In addition, in order to gain insight into the possible explanation for the mother's lack of phenotype, the level of somatic mosaicism and the X-chromosome inactivation pattern were investigated. This study provides new insight into the causes of phenotypic variability in female mutation-carriers and underlines the importance of parental molecular testing for accurate genetic counseling for Danon disease.
-
Clinical Features and Outcomes for Danon Disease: Data from Global Registry
V.S. Escobedo,N. Nguyen,D. Teng,Q.M. Bui,G.S. Ma,M. Brambatti,E. Covarrubias,M. Taylor,E.A. Adler
DOI: https://doi.org/10.1016/j.healun.2019.01.1180
2019-01-01
Abstract:Purpose Danon Disease (DD) is a rare genetic disorder that affects the cardiac, neurologic, and muscular systems in both men and women. Subjects affected typically develop hypertrophic cardiomyopathy (HCM) and end-stage heart failure requiring transplantation. DD is an X-linked disorder with women typically suffering milder disease presentations that develop later in life. Methods A global retrospective registry for DD was created to understand the disease's natural history. Data including the description of clinical features and age of symptom onset was collected from patients across the world (United States, United Kingdom, and Australia). Information was obtained via medical records and questionnaires that were collected from patients and/or their family. Results The registry includes a total of 33 patients with 54.5% being female. The major demographics of patients were Caucasian (96.9%) and from the United States (78.8%). Impartial of the affected organs, males experienced earlier symptoms compared to females (5.5 (2.0-12.0) vs 16.0 (11.5-27.0) years of age, p = 0.002) which resulted in an earlier DD diagnosis in males at (8.0 (4.0-12.0) vs 26.5 (13.0-41.0) years of age, p = 0.023). The frequency of HCM was higher in males as compared to females, (93.3% vs 44.4%) while females had a higher frequency of tachyarrhythmias compared to males (61.1% vs 13.3%). Dilated cardiomyopathy (DCM) was absent in males, however was the first symptom of cardiac disease in two female patients (11.1%). Four males (26.7%) and seven females (38.8%) underwent heart transplantation. Death occurred in one (5.6%) female due to post-transplant complications. Neurological symptoms, primarily manifesting as cognitive impairment were documented in 86.7% of males and 61.1% of females and had a similar age of onset (5.0 (4.0-10.0) vs 8.0 (7.0-15.0) years of age, p = 1). 87.9% of subjects presented with symptomatic skeletal myopathy which was more frequent in males (86.7% vs 64.3%). Conclusion Although DD is an X-linked disorder, significant cardiac morbidity develops in women. Females have a higher prevalence of DCM, which may be secondary to delayed symptom presentation and diagnosis. While DD is a rare diagnosis, healthcare providers should be aware that later clinical manifestations occur in women and should be considered in the differential diagnosis of heart failure. Danon Disease (DD) is a rare genetic disorder that affects the cardiac, neurologic, and muscular systems in both men and women. Subjects affected typically develop hypertrophic cardiomyopathy (HCM) and end-stage heart failure requiring transplantation. DD is an X-linked disorder with women typically suffering milder disease presentations that develop later in life. A global retrospective registry for DD was created to understand the disease's natural history. Data including the description of clinical features and age of symptom onset was collected from patients across the world (United States, United Kingdom, and Australia). Information was obtained via medical records and questionnaires that were collected from patients and/or their family. The registry includes a total of 33 patients with 54.5% being female. The major demographics of patients were Caucasian (96.9%) and from the United States (78.8%). Impartial of the affected organs, males experienced earlier symptoms compared to females (5.5 (2.0-12.0) vs 16.0 (11.5-27.0) years of age, p = 0.002) which resulted in an earlier DD diagnosis in males at (8.0 (4.0-12.0) vs 26.5 (13.0-41.0) years of age, p = 0.023). The frequency of HCM was higher in males as compared to females, (93.3% vs 44.4%) while females had a higher frequency of tachyarrhythmias compared to males (61.1% vs 13.3%). Dilated cardiomyopathy (DCM) was absent in males, however was the first symptom of cardiac disease in two female patients (11.1%). Four males (26.7%) and seven females (38.8%) underwent heart transplantation. Death occurred in one (5.6%) female due to post-transplant complications. Neurological symptoms, primarily manifesting as cognitive impairment were documented in 86.7% of males and 61.1% of females and had a similar age of onset (5.0 (4.0-10.0) vs 8.0 (7.0-15.0) years of age, p = 1). 87.9% of subjects presented with symptomatic skeletal myopathy which was more frequent in males (86.7% vs 64.3%). Although DD is an X-linked disorder, significant cardiac morbidity develops in women. Females have a higher prevalence of DCM, which may be secondary to delayed symptom presentation and diagnosis. While DD is a rare diagnosis, healthcare providers should be aware that later clinical manifestations occur in women and should be considered in the differential diagnosis of heart failure.
-
Case Report: A Novel LAMP2 Splice-Altering Mutation Causes Cardiac-Only Danon Disease
Zongzhe Li,Fei Ma,Rui Li,Zhichao Xiao,Hesong Zeng,Dao Wen Wang
DOI: https://doi.org/10.3389/fcvm.2021.763240
IF: 3.6
2021-11-25
Frontiers in Cardiovascular Medicine
Abstract:Danon disease (DD) is a rare glycogen storage lysosomal disorder caused by mutations in the LAMP2 gene. Patients with DD are usually characterized clinically by severe multisystem syndromes. We describe a specific family with a novel pathogenic splice-altering mutation in the LAMP2 gene (c.741+2T>C) with cardiac-only symptoms (frequent ventricular tachycardia, intraventricular block, and hypertrophic cardiomyopathy). Minigene assays were used to evaluate the consequence of the splice-site mutation in the LAMP2 gene. The results showed that the c.741+2T>C mutation led to extra 6-bp preservation of intron 5 at the junction between exons 5 and 6 during transcriptional processing of the mRNA, which creates a stop codon and truncated the LAMP2 protein to 248-amino-acid residues. The mutant LAMP2 protein was predicted to have a conformational change, lacks the important transmembrane domain, and subsequent protein destabilization.
cardiac & cardiovascular systems
-
Cardiac Phenotype Characterization at MRI in Patients with Danon Disease: A Retrospective Multicenter Case Series
Xiaoyu Wei,Lei Zhao,Jiajun Xie,Yang Liu,Zhicheng Du,Xiaomei Zhong,Weitao Ye,Yining Wang,Yucheng Chen,Minjie Lu,Hui Liu
DOI: https://doi.org/10.1148/radiol.2021203996
IF: 19.7
2021-05-01
Radiology
Abstract:Danon disease (DD) is a rare X-chromosome-linked dominant lysosomal glycogen storage disease. Its features have seldom been reported by using cardiac MRI. This case series aimed to evaluate cardiac features of DD on the basis of MRI observations from five centers in China. From January 2010 to May 2019, 16 patients with DD (13 male patients [81%]; median age, 19 years; age range, 14-44 years) underwent MRI. The most frequent DD cardiomyopathy manifestation was symmetric hypertrophy cardiomyopathy (HCM) phenotype (nine of 16; 56%), followed by asymmetric HCM phenotype (six of 16; 38%) and dilated cardiomyopathy phenotype (one of 16; 6%). The characteristic late gadolinium enhancement features included midbasal septum sparing (14 of 16; 88%) and apex involvement (16 of 16; 100%) with a base-to-apex increasing tendency, free wall involvement (15 of 16; 94%), and extensive subendocardium involvement (14 of 16; 88%). Abnormal T2 signal (seven of 16; 44%) and resting perfusion defect (14 of 16; 88%) were not uncommon in patients with DD. Furthermore, the cardiac MRI features of DD cohort in this study were compared with those of DD in previous literature and with genetically confirmed sarcomeric HCM.
radiology, nuclear medicine & medical imaging
-
Targeting the IKs Channel PKA Phosphorylation Axis to Restore Its Function in High-Risk LQT1 Variants
Ling ZhongZhenzhen YanDexiang JiangKuo-Chan WengYue OuyangHangyu ZhangXiaoqing LinChenxin XiaoHuaiyu YangJing YaoXinjiang KangChanghe WangChen HuangBing ShenSookja Kim ChungZhi-Hong JiangWandi ZhuErwin NeherJonathan R. SilvaPanpan HouDr. Neher's Biophysics Laboratory for Innovative Drug Discovery,State Key Laboratory of Quality Research in Chinese Medicine,Macau University of Science and Technology,Taipa,Macao SAR,China (L.Z.,Z.Y.,D.J.,Y.O.,H.Z.,X.L.,C.X.,C.H.,B.S.,S.K.C.,Z.-H.J.,E.N.,P.H.).Macau University of Science and Technology Zhuhai MUST Science and Technology Research Institute. Zhuhai,Guangdong,China (L.Z.,Z.Y.,D.J.,Y.O.,H.Z.,X.L.,C.X.,C.H.,B.S.,S.K.C.,Z.-H.J.,E.N.,P.H.).Department of Biomedical Engineering,Center for the Investigation of Membrane Excitability Disorders,Cardiac Bioelectricity and Arrhythmia Center,Washington University,St. Louis,MO (K.-C.W.,J.R.S.).Shanghai Key Laboratory of Regulatory Biology,Institute of Biomedical Sciences and School of Life Sciences,East China Normal University (H.Y.).State Key Laboratory of Virology,Hubei Key Laboratory of Cell Homeostasis,College of Life Sciences,TaiKang Center for Life and Medical Sciences,Frontier Science Center for Immunology and Metabolism,Wuhan University,China (J.Y.).Key Laboratory of Medical Electrophysiology,Ministry of Education of China,Collaborative Innovation Center for Prevention and Treatment of Cardiovascular Disease and the Institute of Cardiovascular Research,Southwest Medical University,Luzhou,China (X.K.).Department of Neurosurgery,the Affiliated Hospital of Southwest Medical University,Luzhou,China (X.K.).College of Life Sciences,Liaocheng University,China (X.K.).Department of Neurology,First Affiliated Hospital,Neuroscience Research Center,Key Laboratory of Biomedical Information Engineering of Ministry of Education,School of Life Science and Technology,Xi'an Jiaotong University,China (C.W.).Cardiovascular Medicine Division and Department of Medicine,Brigham and Women's Hospital,Harvard Medical School,Boston,MA (W.Z.).
DOI: https://doi.org/10.1161/circresaha.124.325009
IF: 23.213
2024-08-23
Circulation Research
Abstract:Circulation Research, Ahead of Print. BACKGROUND:The KCNQ1+KCNE1 (IKs) potassium channel plays a crucial role in cardiac adaptation to stress, in which β-adrenergic stimulation phosphorylates the IKschannel through the cyclic adenosine monophosphate (cAMP)/PKA (protein kinase A) pathway. Phosphorylation increases the channel current and accelerates repolarization to adapt to an increased heart rate. Variants in KCNQ1 can cause long-QT syndrome type 1 (LQT1), and those with defective cAMP effects predispose patients to the highest risk of cardiac arrest and sudden death. However, the molecular connection between IKschannel phosphorylation and channel function, as well as why high-risk LQT1 mutations lose cAMP sensitivity, remain unclear.METHODS:Regular patch clamp and voltage clamp fluorometry techniques were utilized to record pore opening and voltage sensor movement of wild-type and mutant KCNQ1/IKschannels. The clinical phenotypic penetrance of each LQT1 mutation was analyzed as a metric for assessing their clinical risk. The patient-specific–induced pluripotent stem-cell model was used to test mechanistic findings in physiological conditions.RESULTS:By systematically elucidating mechanisms of a series of LQT1 variants that lack cAMP sensitivity, we identified molecular determinants of IKschannel regulation by phosphorylation. These key residues are distributed across the N-terminus of KCNQ1 extending to the central pore region of IKs. We refer to this pattern as the IKschannel PKA phosphorylation axis. Next, by examining LQT1 variants from clinical databases containing 10 579 LQT1 carriers, we found that the distribution of the most high-penetrance LQT1 variants extends across the IKschannel PKA phosphorylation axis, demonstrating its clinical relevance. Furthermore, we found that a small molecule, ML277, which binds at the center of the phosphorylation axis, rescues the defective cAMP effects of multiple high-risk LQT1 variants. This finding was then tested in high-risk patient-specific induced pluripotent stem cell–derived cardiomyocytes, where ML277 remarkably alleviates the beating abnormalities.CONCLUSIONS:Our findings not only elucidate the molecular mechanism of PKA-dependent IKschannel phosphorylation but also provide an effective antiarrhythmic strategy for patients with high-risk LQT1 variants.
cardiac & cardiovascular systems,peripheral vascular disease,hematology
-
Letter by Jin-shan and Xue-bin Regarding Article, "Genotype-Phenotype Correlation of SCN5A Mutation for the Clinical and Electrocardiographic Characteristics of Probands with Brugada Syndrome: A Japanese Multicenter Registry".
Jing He,Xuebin Li
DOI: https://doi.org/10.1161/circulationaha.117.030553
IF: 37.8
2017-01-01
Circulation
Abstract:HomeCirculationVol. 136, No. 23Letter by Jin-shan and Xue-bin Regarding Article, “Genotype-Phenotype Correlation of SCN5A Mutation for the Clinical and Electrocardiographic Characteristics of Probands With Brugada Syndrome: A Japanese Multicenter Registry” Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBLetter by Jin-shan and Xue-bin Regarding Article, “Genotype-Phenotype Correlation of SCN5A Mutation for the Clinical and Electrocardiographic Characteristics of Probands With Brugada Syndrome: A Japanese Multicenter Registry” He Jin-shan, MD and Li Xue-bin, MD He Jin-shanHe Jin-shan Department of Cardiology, Beijing Key Laboratory of Early Prediction and Intervention of Acute Myocardial Infarction, Peking University People’s Hospital, Beijing, China. Search for more papers by this author and Li Xue-binLi Xue-bin Department of Cardiology, Beijing Key Laboratory of Early Prediction and Intervention of Acute Myocardial Infarction, Peking University People’s Hospital, Beijing, China. Search for more papers by this author Originally published5 Dec 2017https://doi.org/10.1161/CIRCULATIONAHA.117.030553Circulation. 2017;136:2287–2288To the Editor:We read with great interest the article by Yamagata et al1 about the genotype-phenotype correlation of SCN5A mutations for the clinical and electrocardiographic characteristics of probands with Brugada syndrome, which indicates that patients with Brugada syndrome with SCN5A mutations exhibit more conduction abnormalities on ECG and have a higher risk for cardiac events. This study has a great effect on making the genotype-phenotype correlation of SCN5A mutations as a predictor of cardiac events in Brugada syndrome, which can improve the risk stratification systems for Brugada syndrome. However, we have 3 questions about this study. First, patients with SCN5A mutations have a higher risk for cardiac events, but there is a trend toward a lower rate of VF/VT inducibility in them during the EP study. What is the reason for this discrepancy? Why are patients with SCN5A mutations difficult to induce malignant arrhythmia in with rigorous stimulation but are prone to cardiac events in real life? Second, patients with SCN5A mutations exhibit more conduction abnormalities on ECG and have a higher risk for cardiac events in this study. What is the relationship between conduction abnormalities and higher cardiac event risks? Are they both the presentations of SCN5A mutations? Or do SCN5A mutations cause conduction abnormalities first and then conduction abnormalities make cardiac events risk higher? Third, SCN5A mutations are related to Brugada syndrome as well as other inherited cardiomyopathies such as dilated cardiomyopathy, long QT syndrome type 3, and arrhythmogenic right ventricular dysplasia.2,3 Do these patients also have a higher risk for cardiac events? Or is this effect confined only to Brugada syndrome? We hope to have a profound understanding of Brugada syndrome with these questions.He Jin-shan, MDLi Xue-bin, MDDisclosuresNone.FootnotesCirculation is available at http://circ.ahajournals.org.References1. Yamagata K, Horie M, Aiba T, Ogawa S, Aizawa Y, Ohe T, Yamagishi M, Makita N, Sakurada H, Tanaka T, Shimizu A, Hagiwara N, Kishi R, Nakano Y, Takagi M, Makiyama T, Ohno S, Fukuda K, Watanabe H, Morita H, Hayashi K, Kusano K, Kamakura S, Yasuda S, Ogawa H, Miyamoto Y, Kapplinger JD, Ackerman MJ, Shimizu W. Genotype-phenotype correlation of SCN5A mutation for the clinical and electrocardiographic characteristics of probands with Brugada syndrome: a Japanese multicenter registry.Circulation. 2017; 135:2255–2270. doi: 10.1161/CIRCULATIONAHA.117.027983.LinkGoogle Scholar2. McNair WP, Ku L, Taylor MR, Fain PR, Dao D, Wolfel E, Mestroni L; Familial Cardiomyopathy Registry Research Group. SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia.Circulation. 2004; 110:2163–2167. doi: 10.1161/01.CIR.0000144458.58660.BB.LinkGoogle Scholar3. Remme CA. Cardiac sodium channelopathy associated with SCN5A mutations: electrophysiological, molecular and genetic aspects.J Physiol. 2013; 591:4099–4116. doi: 10.1113/jphysiol.2013.256461.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetails December 5, 2017Vol 136, Issue 23 Advertisement Article InformationMetrics © 2017 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.117.030553PMID: 29203569 Originally publishedDecember 5, 2017 PDF download Advertisement SubjectsCardiomyopathyRisk Factors
-
An International Longitudinal Natural History Study of Danon Disease Patients: Unique Cardiac Trajectories Identified Based on Sex and Heart Failure Outcomes
Kimberly Hong,Emily A Eshraghian,Tarek Khedro,Alessia Argirò,Jennifer Attias,Garrett R Storm,Melina Tsotras,Tanner Bloks,Isaiah Jackson,Elijah Ahmad,Sharon Graw,Luisa Mestroni,Quan Minh Bui,Jonathan Schwartz,Stuart Turner,Eric D. Adler,Matthew Taylor
DOI: https://doi.org/10.1101/2024.05.21.24307720
2024-05-22
Abstract:Introduction: Danon disease (DD) is a rare X-linked dominant cardioskeletal myopathy caused by mutations in the lysosome-associated membrane protein-2 gene. Though the severe morbidity of disease in males is well established, longitudinal studies describing the trajectory of cardiovascular disease in both sexes have not been performed. Herein we performed an analysis using the International Danon Disease Registry, a retrospective dataset that includes longitudinal data from a cohort of males and females with DD.
Methods: Data were from the International Danon Disease Registry and includes patients from 2005 to 2022. Records were obtained from the first episode of care to the date of enrollment and included demographics, clinical characteristics, echocardiographic and laboratory values, and outcomes. The primary outcome in this study was a heart failure (HF) composite defined as either transplant (TXP), left ventricular assist device (LVAD) or death.
Results: The analysis included 116 DD patients: female (n=64, 55%) and male (n=52, 45%). Median age of diagnosis for the entire cohort was 15.2 years (10.0-25.2 years), and 21.9 years (15.0-34.9 years) and 12.4 years (7.1-15.6 years) for females and males respectively. The incidence of HF outcome was higher in males compared to females (p<0.001). Regarding trends in echocardiographic parameters over time, LVEF decreased and LVEDD increased regardless of sex and HF outcome, however, rate of change was increased in patients who experienced a HF outcome in both sexes. Increasing LV mass occurs in males but not females. Consistent with this, LV wall hypertrophy continues in males who have not yet experienced a HF outcome and stabilizes prior to HF outcome, while females have progressive LV thinning regardless of HF outcome. Analyses stratified by age of HF outcome in females found two distinct groups of females, one who experienced HF outcome prior to 26 years of age and another after.
Conclusions: In this largest longitudinal natural history study of DD to date, we confirmed that males present on average a decade earlier and demonstrate more progressive cardiac hypertrophy and heart failure than females. Of note, there may be a subset of females who are phenotypically similar to males with profound LV hypertrophy that appears to stabilize or regress prior to HF outcome. Correlations between structural changes including LV hypertrophy, dilation and dysfunction and disease progression may allow for risk stratification of Danon patients and refinement of treatment algorithms while also informing therapeutic trial design.